Emergent Biosolutions (NYSE:EBS) is a global life sciences company dedicated to the development, manufacture and delivery of vaccines and antibody therapies that address public health threats. The company’s portfolio encompasses a range of biodefense and infectious disease countermeasures, including the U.S.‐licensed anthrax vaccine BioThrax® and the smallpox vaccine ACAM2000®. In addition to its proprietary products, Emergent offers contract development and manufacturing services for governments and commercial partners, with specialized capabilities in large‐scale biologics production.
Since its founding in 1998 and subsequent initial public offering in 2006, Emergent has expanded through strategic acquisitions such as Cangene Corporation and Adapt Pharma, broadening its product offerings to include treatments for opioid overdose and other critical care needs. The company’s Infectious Disease segment has introduced naloxone nasal spray under the Narcan® brand, demonstrating its commitment to addressing both biodefense and emerging public health crises. Emergent’s vaccine development pipeline also targets diseases such as Zika and chikungunya, reflecting its focus on readiness for future outbreaks.
Headquartered in Gaithersburg, Maryland, Emergent BioSolutions serves customers across North America, Europe and the Asia-Pacific region, with key government clients including the U.S. Department of Health and Human Services and various defence agencies. Its manufacturing facilities, located in the United States and Puerto Rico, are designed to meet stringent regulatory and security standards required for national stockpile products. The company has also forged partnerships with global health organizations to support vaccine access in emerging markets.
Under the leadership of President and Chief Executive Officer Robert G. Kramer Jr., Emergent’s executive team brings deep expertise in biotechnology, government contracting and large‐scale manufacturing. Guided by a board of directors with backgrounds in public health, finance and regulatory affairs, the company continues to invest in research and development, facility expansion and strategic collaborations to strengthen global preparedness against current and future health threats.
